PCN-101

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NamePCN-101
Drug Alias NamePCN-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor antagonists
TargetsGlutamate [NMDA] receptor
Therapy Area/IndicationsDepressive Disorder, Treatment-Resistant
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAtai Life Sciences NV
China Registration ClassN/A

Develop Information

Active CompaniesAtai Life Sciences NVPerception NeuroscienceOtsuka Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, Treatment-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A